← Evidence library

BIB_262

Moderna/Merck KEYNOTE-942 5-year follow-up of mRNA-4157 (V940/intismeran autogene) + pembrolizumab in resected Stage III/IV melanoma.

Evidence grade

B

Tier

3 (press release + early follow-up; not yet peer-reviewed at 5-yr)

Cited by tasks

17, 18, 22a

Identifiers

—

Full extracted findings & patient-implication analysis: bibliography/BIB_262/findings.md (research corpus). This page is a short context summary — not individualised medical advice.